The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
In Vitro Resistance Studies of Hepatitis C Virus Serine Protease Inhibitors, VX-950 and BILN 2061
Open accessAbstract
We have used a structure-based drug design approach to identify small molecule inhibitors of the hepatitis C virus (HCV) NS3.4A protease as potential candidates for new anti-HCV therapies. VX-950 is a potent NS3.4A protease inhibitor that was recently selected as a clinical development candidate for hepatitis C treatment. In this report, we describe in vitro resistance studies using a subgenomic replicon system to compare VX-950 with another HCV NS3.4A protease inhibitor, BILN 2061, for which the Phase I clinical trial results were reported recently. Distinct drug-resistant substitutions of a single amino acid were identified in the HCV NS3 serine protease domain for both inhibitors. The resistance conferred by these mutations was confirmed by characterization of the mutant enzymes and replicon cells that contain the single amino acid substitutions. The major BILN 2061-resistant mutations at Asp(168) are fully susceptible to VX-950, and the dominant resistant mutation against VX-950 at Ala(156) remains sensitive to BILN 2061. Modeling analysis suggests that there are different mechanisms of resistance to VX-950 and BILN 2061.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McHutchison, J. G., Gordon, S. C., Schiff, E. R., Shiffman, M. L., Lee, W. M., Rustgi, V. K., Goodman, Z. D., Ling, M.-H., Cort, S., & Albrecht, J. K. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811193392101 · Cited by 3,465
Replication of Subgenomic Hepatitis C Virus RNAs in a Hepatoma Cell Line
Lohmann, V., Körner, F., Koch, J.-O., Herian, U., Theilmann, L., & Bartenschlager, R. (1999) · Science · doi:10.1126/science.285.5424.110 · Cited by 2,814
Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon-α Therapy
Neumann, A. U., Lam, N. P., Dahari, H., Gretch, D. R., Wiley, T. E., Layden, T. J., & Perelson, A. S. (1998) · Science · doi:10.1126/science.282.5386.103 · Cited by 2,113
Efficient Initiation of HCV RNA Replication in Cell Culture
Blight, K. J., Kolykhalov, A. A., & Rice, C. M. (2000) · Science · doi:10.1126/science.290.5498.1972 · Cited by 1,412
Davis, G. L., Esteban-Mur, R., Rustgi, V., Hoefs, J., Gordon, S. C., Trepo, C., Shiffman, M. L., Zeuzem, S., Craxi, A., Ling, M.-H., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811193392102 · Cited by 1,282
Epidemiology of Hepatitis C: Geographic Differences and Temporal Trends
Wasley, A., & Alter, M. J. (2000) · Seminars in Liver Disease · doi:10.1055/s-2000-9506 · Cited by 979
An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus
Lamarre, D., Anderson, P. C., Bailey, M., Beaulieu, P., Bolger, G., Bonneau, P., Bös, M., Cameron, D. R., Cartier, M., Cordingley, M. G., et al. (2003) · Nature · doi:10.1038/nature02099 · Cited by 917
Expression and identification of hepatitis C virus polyprotein cleavage products
Grakoui, A., Wychowski, C., Lin, C., Feinstone, S. M., & Rice, C. M. (1993) · Journal of Virology · doi:10.1128/jvi.67.3.1385-1395.1993 · Cited by 898
Self-citationKinetics of the reversible inhibition of enzyme-catalysed reactions by tight-binding inhibitors
Morrison, J. F. (1969) · Biochimica et Biophysica Acta (BBA) - Enzymology · doi:10.1016/0005-2744(69)90420-3 · Cited by 814
Alter, H. J., & Seeff, L. B. (2000) · Seminars in Liver Disease · doi:10.1055/s-2000-9505 · Cited by 736
Kim, J. L., Morgenstern, K. A., Lin, C., Fox, T., Dwyer, M. D., Landro, J. A., Chambers, S. P., Markland, W., Lepre, C. A., O'Malley, E. T., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81351-3 · Cited by 727
Self-citationLai, C., Dienstag, J., Schiff, E., Leung, N. W. Y., Atkins, M., Hunt, C., Brown, N., Woessner, M., Boehme, R., & Condreay, L. (2003) · Clinical Infectious Diseases · doi:10.1086/368083 · Cited by 634
Grakoui, A., McCourt, D. W., Wychowski, C., Feinstone, S. M., & Rice, C. M. (1993) · Journal of Virology · doi:10.1128/jvi.67.5.2832-2843.1993 · Cited by 610
Kolykhalov, A. A., Mihalik, K., Feinstone, S. M., & Rice, C. M. (2000) · Journal of Virology · doi:10.1128/jvi.74.4.2046-2051.2000 · Cited by 606
Hirsch, M. S., Brun‐Vezinet, F., Clotet, B., Conway, B., Kuritzkes, D. R., D’Aquila, R. T., Demeter, L. M., Hammer, S. M., Johnson, V. A., Loveday, C., et al. (2003) · Clinical Infectious Diseases · doi:10.1086/375597 · Cited by 514
Love, R. A., Parge, H. E., Wickersham, J. A., Hostomsky, Z., Habuka, N., Moomaw, E. W., Adachi, T., & Hostomska, Z. (1996) · Cell · doi:10.1016/s0092-8674(00)81350-1 · Cited by 509
Bartenschlager, R., Ahlborn-Laake, L., Mous, J., & Jacobsen, H. (1993) · Journal of Virology · doi:10.1128/jvi.67.7.3835-3844.1993 · Cited by 462
Yao, N., Reichert, P., Taremi, S. S., Prosise, W. W., & Weber, P. C. (1999) · Structure · doi:10.1016/s0969-2126(00)80025-8 · Cited by 391
Bartenschlager, R., Lohmann, V, Wilkinson, T., & Koch, J. O. (1995) · Journal of Virology · doi:10.1128/jvi.69.12.7519-7528.1995 · Cited by 241
Lin, C., Thomson, J. A., & Rice, C. M. (1995) · Journal of Virology · doi:10.1128/jvi.69.7.4373-4380.1995 · Cited by 221
Self-citationDe Francesco, R., Tomei, L., Altamura, S., Summa, V., & Migliaccio, G. (2003) · Antiviral Research · doi:10.1016/s0166-3542(03)00028-7 · Cited by 186
Failla, C. M., Tomei, L., & Francesco, R. D. (1995) · Journal of Virology · doi:10.1128/jvi.69.3.1769-1777.1995 · Cited by 158
Inhibition of the Hepatitis C Virus NS3/4A Protease
Marco, S. D., Rizzi, M., Volpari, C., Walsh, M. A., Narjes, F., Colarusso, S., Francesco, R. D., Matassa, V. G., & Sollazzo, M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.10.7152 · Cited by 127
Treatment of chronic hepatitis C: A systematic review
Chander, G., Sulkowski, M., Jenckes, M. W., Torbenson, M. S., Herlong, H. F., Bass, E. B., & Gebo, K. A. (2002) · Hepatology · doi:10.1002/hep.1840360718 · Cited by 100
THE NATURAL HISTORY OF HEPATITIS C VIRUS INFECTION
Kenny-Walsh, E. (2001) · Clinics in Liver Disease · doi:10.1016/s1089-3261(05)70204-x · Cited by 32
Cited by
Sarrazin, C., Kieffer, T. L., Bartels, D., Hanzelka, B., Müh, U., Welker, M., Wincheringer, D., Zhou, Y., Chu, H., Lin, C., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.02.037 · Cited by 616
Self-citationResistance to Direct Antiviral Agents in Patients With Hepatitis C Virus Infection
Sarrazin, C., & Zeuzem, S. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.11.055 · Cited by 504
The design of drugs for HIV and HCV
Clercq, E. D. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2424 · Cited by 430
The importance of resistance to direct antiviral drugs in HCV infection in clinical practice
Sarrazin, C. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.09.011 · Cited by 423
Challenges and successes in developing new therapies for hepatitis C
De Francesco, R., & Migliaccio, G. (2005) · Nature · doi:10.1038/nature04080 · Cited by 411
Metadata
- Authors
- Lin, C., Lin, K., Luong, Y.-P., Rao, B. G., Wei, Y.-Y., Brennan, D. L., Fulghum, J. R., Hsiao, H.-M., Ma, S., Maxwell, J. P., Cottrell, K. M., Perni, R. B., Gates, C. A., & Kwong, A. D.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2004-04
- Volume
- 279
- Issue
- 17
- Pages
- 17508-17514
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2139677692
- Cited by
- 288
- References
- 25
- FWCI
- 21.01
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.